Humoral and cellular immune responses to Copolymer 1 in multiple sclerosis patients treated with Copaxone (Q43562148)

24 November 2017

Humoral and cellular immune responses to Copolymer 1 in multiple sclerosis patients treated with Copaxone (English)

1 reference

24 November 2017

0 references

Brenner T

1

1 reference

24 November 2017

Arnon R

2

1 reference

24 November 2017

Sela M

3

1 reference

24 November 2017

Abramsky O

4

1 reference

24 November 2017

Meiner Z

5

1 reference

24 November 2017

Riven-Kreitman R

6

1 reference

24 November 2017

Tarcik N

7

1 reference

24 November 2017

Teitelbaum D

8

1 reference

24 November 2017

1 April 2001

1 reference

Journal of Neuroimmunology

24 November 2017

1 reference

24 November 2017

115

1 reference

24 November 2017

1-2

1 reference

24 November 2017

152-160

1 reference

T suppressor hybridomas and interleukin-2-dependent lines induced by copolymer 1 or by spinal cord homogenate down-regulate experimental allergic encephalomyelitis

24 November 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2801%2900250-8

7 January 2021

Copolymer 1 induces T cells of the T helper type 2 that crossreact with myelin basic protein and suppress experimental autoimmune encephalomyelitis

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2801%2900250-8

7 January 2021

Bystander suppression of experimental autoimmune encephalomyelitis by T cell lines and clones of the Th2 type induced by copolymer 1

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2801%2900250-8

7 January 2021

T cells responsive to myelin basic protein in patients with multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2801%2900250-8

7 January 2021

The development of Cop 1 (Copaxone), an innovative drug for the treatment of multiple sclerosis: personal reflections

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2801%2900250-8

7 January 2021

Chemically Defined Antiviral Vaccines

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2801%2900250-8

7 January 2021

Multiple sclerosis: an autoimmune disease of multifactorial etiology

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2801%2900250-8

7 January 2021

A pilot trial of Cop 1 in exacerbating-remitting multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2801%2900250-8

7 January 2021

A monoclonal antibody raised to corpus callosum extract reacts with 2',3'-cyclic nucleotide 3'-phosphohydrolase.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2801%2900250-8

7 January 2021

Immunogenic potentials of copolymer I in normal human lymphocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2801%2900250-8

7 January 2021

Human cellular immune response to copolymer I and myelin basic protein

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2801%2900250-8

7 January 2021

Autoreactivity to myelin antigens: myelin/oligodendrocyte glycoprotein is a prevalent autoantigen

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2801%2900250-8

7 January 2021

Glatiramer acetate (Copaxone) induces degenerate, Th2-polarized immune responses in patients with multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2801%2900250-8

7 January 2021

Cell-mediated immune response to copolymer I in multiple sclerosis measured by the macrophage procoagulant activity assay

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2801%2900250-8

7 January 2021

Immunologic mechanisms and therapy in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2801%2900250-8

7 January 2021

Basic encephalitogenic protein: A simplified purification on sulphoethyl-sephadex

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2801%2900250-8

7 January 2021

The role of autoimmune T lymphocytes in the pathogenesis of multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2801%2900250-8

7 January 2021

Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. Copolymer 1 Multiple Sclerosis Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2801%2900250-8

7 January 2021

Predominance of the autoimmune response to myelin oligodendrocyte glycoprotein (MOG) in multiple sclerosis: reactivity to the extracellular domain of MOG is directed against three main regions

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2801%2900250-8

7 January 2021

Immunological aspects of demyelinating diseases

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2801%2900250-8

7 January 2021

Treatment of multiple sclerosis with copolymer-1 (Copaxone): implicating mechanisms of Th1 to Th2/Th3 immune-deviation.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2801%2900250-8

7 January 2021

Multiple sclerosis: comparison of copolymer-1- reactive T cell lines from treated and untreated subjects reveals cytokine shift from T helper 1 to T helper 2 cells

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2801%2900250-8

7 January 2021

Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2801%2900250-8

7 January 2021

The epigenetics of multiple sclerosis: clues to etiology and a rationale for immune therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2801%2900250-8

7 January 2021

Major T-cell responses in multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2801%2900250-8

7 January 2021

Suppression of experimental allergic encephalomyelitis by a synthetic polypeptide

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2801%2900250-8

7 January 2021

Cross-reactions and specificities of monoclonal antibodies against myelin basic protein and against the synthetic copolymer 1

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2801%2900250-8

7 January 2021

Synthetic copolymer 1 inhibits human T-cell lines specific for myelin basic protein

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2801%2900250-8

7 January 2021

Anti-myelin basic protein and anti-proteolipid protein specific forms of multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2801%2900250-8

7 January 2021

In vivo and in vitro immunological cross-reactions between basic encephalitogen and synthetic basic polypeptides capable of suppressing experimental allergic encephalomyelitis

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2801%2900250-8

7 January 2021

Molecular requirements involved in suppression of eae by synthetic basic copolymers of amino acids

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2801%2900250-8

7 January 2021

10.1016/S0165-5728(01)00250-8

Identifiers

DOI

1 reference

24 November 2017

1 reference